Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLCG1 | P19174 | 1/20 | 0.35 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.32 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | ELANE | P08246 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7730048 | 0.95 | PLCG1 (0.36) | PLCG1DPP8DPP9HTR2AELANE | |
| SCHEMBL6891104 | 0.92 | PLCG1 (0.32) | PLCG1DPP8DPP9 | |
| SCHEMBL6624626 | 0.88 | KDM4E (0.34) | PLCG1DPP8DPP9TDP1KDM4E | |
| SCHEMBL6889515 | 0.87 | PLCG1 (0.32) | PLCG1DPP8DPP9HTR2AELANE | |
| SCHEMBL7728210 | 0.87 | PLCG1 (0.33) | PLCG1DPP8DPP9 | |
| SCHEMBL7722500 | 0.86 | PLCG1 (0.37) | PLCG1HTR2AELANEALDH1A1MAPT | |
| SCHEMBL7722214 | 0.86 | PLCG1 (0.37) | PLCG1TDP1HTR2AELANEALDH1A1 | |
| SCHEMBL8196175 | 0.85 | PLCG1 (0.38) | PLCG1TDP1HTR2AELANEALDH1A1 | |
| SCHEMBL7722332 | 0.85 | PLCG1 (0.37) | PLCG1HTR2AELANEALDH1A1MAPT | |
| SCHEMBL7728648 | 0.84 | PLCG1 (0.37) | PLCG1TDP1HTR2AELANEALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6677331-B2 | HAVING SUBSTITUTED IMIDAZO(5,1-B)THIAZOLE GROUP AT 2-POSITION; MICROBIOCIDES AGAINST BETA-LACTAMASE PRODUCING BACTERIA AND RESISTANT PSEUDOMONAS | MEIJI SEIKA KAISHA, LTD. (JP) | 2004-01-13 | — | — | US | disclosed |
| US-20030149016-A1 | Novel carbapenem derivatives | KANO YUKO (JP) | 2003-08-07 | — | — | US | disclosed |
| US-6458780-B1 | IMIDAZO(5,1-B)THIAZOLE GROUP AT THE 2-POSITION ON THE CARBAPENEM RING HAVE HIGH ANTI-MICROBIAL ACTIVITIES AGAINST .BETA.-LACTAMASE PRODUCING BACTERIA, MRSA, RESISTANT-PSEUDOMONAS AERUGINOSA, PRSP, ENTEROCOCCI, AND | MEIJI SEIKA KAISHA, LTD. (JP) | 2002-10-01 | — | — | US | disclosed |
| EP-1101766-A1 | NOVEL CARBAPENEM DERIVATIVES | MEIJI SEIKA KAISHA LTD. (JP) | 2001-05-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149016-A1 | Novel carbapenem derivatives | DPEP1, TMPRSS15, STK35 | PLCG1 1638/4885DPP8 85/4885DPP9 88/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.